본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Technologies in laboratory diagnostics are changing fast with progress in understanding and therapy of diseases. Unfortunately, new analyzers are often needed to be installed in a clinical laboratory to implement such techniques. The demand for new hardware is a bottleneck in improving the diagnostic services for many facilities with limited resources. In this regard, hemostasis laboratories take a slightly different position.

Because many in vitro diagnostic tests target the functional aspects of hemostasis, further meaningful information can be obtained from the same analyzers as in current use.

Automated coagulometers are good candidates for such further utilization. Clot waveform analysis is a leading example. Behind the simple values reported as clotting time, clotting curves exist that represent the process of fibrin clot formation. Clot waveform analysis examines the clotting curves and derives new parameters other than clotting times. The clot waveform parameters are now in active use in assessing the hemostatic potential of hemorrhagic patients. Clinical application of coagulometers can also be widened by modifying the reagent formulation. For example, the chromogenic factor VIII assay with bovine source reagent compositions has recently been introduced for hemophilia A patients on emicizumab prophylaxis. Also, new immunoturbidimetric functional assays for von Willebrand factor have been developed recently. Thus, new clinically relevant information can be mined from the automated coagulometers that are based on old technology.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Assessing frailty using comprehensive geriatric assessment in older patients with hematologic malignancy Jung-Yeon Choi, Kwang-Il Kim p. 1-5
Evaluation and management of platelet transfusion refractoriness Hee-Jeong Youk, Sang-Hyun Hwang, Heung-Bum Oh, Dae-Hyun Ko p. 6-10
Diagnostic workup of inherited platelet disorders Bohyun Kim p. 11-19
Diagnosis and management of monoclonal gammopathy of clinical significance Hyungwoo Cho p. 20-26
Update on the POEMS syndrome Yu Ri Kim p. 27-31
FLT3 mutations in acute myeloid leukemia : a review focusing on clinically applicable drugs Jae-Sook Ahn, Hyeoung-Joon Kim p. 32-36
Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang p. 37-43
Challenging issues in the management of cancer-associated venous thromboembolism Ho-Young Yhim p. 44-48
Overview of inherited bone marrow failure syndromes Meerim Park p. 49-54
Basic immunohistochemistry for lymphoma diagnosis Junhun Cho p. 55-61
Update on primary plasma cell leukemia Sung-Hoon Jung, Je-Jung Lee p. 62-66
Human acute myeloid leukemia stem cells : evolution of concept Dong-Yeop Shin p. 67-74
Staging and response assessment of lymphoma : a brief review of the Lugano classification and the role of FDG-PET/CT Kwai Han Yoo p. 75-78
Diagnosis and management of thrombocytopenia in pregnancy Young Hoon Park p. 79-85
Genetics and genomics of bone marrow failure syndrome Hyun-Young Kim, Hee-Jin Kim, Sun-Hee Kim p. 86-92
Advances in laboratory assessment of thrombosis and hemostasis Jaewoo Song p. 93-100
Advances in prophylaxis and treatment of invasive fungal infections : perspectives on hematologic diseases Hyojin Ahn, Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee p. 101-111
Recent advances in treatments of adult immune thrombocytopenia Dae Sik Kim p. 112-119
Treatment of indolent lymphoma Seong Hyun Jeong p. 120-129

참고문헌 (52건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Lippi G, Plebani M, Favaloro EJ. Technological advances in the hemostasis laboratory. Semin Thromb Hemost 2014;40:178-85. 미소장
2 Lippi G, Cadamuro J, Danese E, et al. Internal quality assurance of HIL indices on Roche Cobas c702. PLoS One 2018;13:e0200088. 미소장
3 Abildgaard U, Lie M, Odegård OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977;11:549-53. 미소장
4 Goodnight SH Jr, Schaeffer JL, Sheth K. Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assays. Am J Clin Pathol 1980;73:639-47. 미소장
5 Dang QD, Di Cera E. Chromogenic substrates selective for activated protein C. Blood 1997;89:2220-2. 미소장
6 Prasa D, Sturzebecher J. Determination of activated factor IX in factor IX concentrates with a chromogenic substrate. Thromb Res 1998;92:99-102. 미소장
7 Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost 2016;14:1428-35. 미소장
8 Whicher JT, Price CP, Spencer K. Immunonephelometric and immunoturbidimetric assays for proteins. Crit Rev Clin Lab Sci 1983;18:213-60. 미소장
9 Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci PM. International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost 1998;79:439-43. 미소장
10 van den Besselaar AMHP, van Rijn CJJ, Abdoel CF, et al. Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: harmonizing the manual tilt tube method. J Thromb Haemost 2020;18:1986-94. 미소장
11 Favaloro EJ, Lippi G. Recent advances in mainstream hemostasis diagnostics and coagulation testing. Semin Thromb Hemost 2019;45:228-46. 미소장
12 Magnette A, Chatelain M, Chatelain B, Ten Cate H, Mullier F. Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thromb J 2016;14:49. 미소장
13 Woolley A, Golmard JL, Kitchen S. Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STACompact-Max analyser. Int J Lab Hematol 2016;38:375-88. 미소장
14 Nougier C, Jousselme E, Sobas F, Pousseur V, Négrier C. Effects of hemolysis, bilirubin, and lipemia interference on coagulation tests detected by two analytical systems. Int J Lab Hematol 2020;42:88-94. 미소장
15 Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008;111:4854-61. 미소장
16 Shima M, Matsumoto T, Fukuda K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002;87:436-41. 미소장
17 Matsumoto T, Shima M, Takeyama M, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006;4:377-84. 미소장
18 Shima M, Thachil J, Nair SC, Srivastava A, Scientific and Standardization Committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013;11:1417-20. 미소장
19 Nogami K, Matsumoto T, Tabuchi Y, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost 2018;16:1078-88. 미소장
20 Nakajima Y, Nogami K, Yada K, et al. Emicizumab improves ex vivo clotting function in patients with mild/moderate hemophilia A. Thromb Haemost 2020;120:968-76. 미소장
21 Takeyama M, Furukawa S, Yada K, et al. Ex vivo prediction of comprehensive coagulation potential using simulated blood concentrations of emicizumab in patients with acquired hemophilia A. Thromb Haemost 2021;121:1289-98. 미소장
22 Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors. Br J Haematol 2020;190:727-35. 미소장
23 Milos M, Coen Herak D, Mahmoud Hourani Soutari N, et al. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype. Int J Lab Hematol 2021;43:273-80. 미소장
24 Shimonishi N, Ogiwara K, Oda Y, et al. Inhibitor index in the clot waveform analysis-based mixing test differentiates among hemophilia A without and with inhibitors, and lupus anticoagulant. Thromb Haemost 2021;121:792-9. 미소장
25 Toh CH, Samis J, Downey C, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002;100:2522-9. 미소장
26 Shimonishi N, Ogiwara K, Oda Y, et al. A novel assessment of factor VIII activity by template matching utilizing weighted average parameters from comprehensive clot waveform analysis. Thromb Haemost 2021;121:164-73. 미소장
27 Pavlova A, Delev D, Pezeshkpoor B, Müller J, Oldenburg J. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thromb Haemost 2014;111:851-61. 미소장
28 Trossaërt M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy:using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008;6:486-93. 미소장
29 Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346--＞Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A? Haemophilia 2008;14:78-80. 미소장
30 Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016;14:248-61. 미소장
31 Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377:809-18. 미소장
32 Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018;379:811-22. 미소장
33 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019;17:479-86. 미소장
34 Castaman G, Santoro C, Coppola A, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus 2020;18:143-51. 미소장
35 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019;119:1084-93. 미소장
36 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019;119:1384-93. 미소장
37 Jenkins PV, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia 2020;26:151-5. 미소장
38 Lowe A, Kitchen S, Jennings I, Kitchen DP, Woods TAL, Walker ID. Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise. Haemophilia 2020;26:1087-91. 미소장
39 Kasper C, Aledort L, Counts R, Edson J, Frantantoni J, Green D. Letter: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:869-72. 미소장
40 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-51. 미소장
41 Korte W, Riesen W. Latex-enhanced immunoturbidimetry allows D-dimer determination in plasma and serum samples. Clin Chem 2000;46:871-2. 미소장
42 Knecht MF, Heinrich F. Clinical evaluation of an immunoturbidimetric D-dimer assay in the diagnostic procedure of deep vein thrombosis and pulmonary embolism. Thromb Res 1997;88:413-7. 미소장
43 Christophe O, Rouault C, Obert B, Piétu G, Meyer D, Girma JP. A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol 1995;90:195-203. 미소장
44 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424. 미소장
45 Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol 2005;42:15-28. 미소장
46 Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology 2016;48:303-18. 미소장
47 Mohammed S, Favaloro EJ. Laboratory testing for von Willebrand factor: factor VIII binding (for 2N VWD). Methods Mol Biol 2017;1646:461-72. 미소장
48 Patzke J, Favaloro EJ. Laboratory testing for von Willebrand factor activity by glycoprotein Ib binding assays (VWF:GPIb). Methods Mol Biol 2017;1646:453-60. 미소장
49 Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 2014;134:1292-300. 미소장
50 Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:1345-50. 미소장
51 Favaloro EJ. Diagnosis or exclusion of von Willebrand disease using laboratory testing. Methods Mol Biol 2017;1646:391-402. 미소장
52 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2016;141:202-11. 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차